Title:
ANTIBODIES SPECIFIC FOR IL-17A FUSED TO HYALURONAN BINDING PEPTIDE TAGS
Document Type and Number:
WIPO Patent Application WO/2015/198217
Kind Code:
A3
Abstract:
The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17A and a peptide tag that binds hyaluronan (HA). The disclosure more specifically relates to specific antibodies and proteins that are IL-17A antagonists (inhibit the activities of IL- 17A and IL-17AF) and are capable of inhibiting IL-17A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.
Inventors:
DI PADOVA FRANCO E (CH)
GHOSH JOY (US)
HUBER THOMAS (CH)
RONDEAU JEAN-MICHEL RENE (CH)
GHOSH JOY (US)
HUBER THOMAS (CH)
RONDEAU JEAN-MICHEL RENE (CH)
Application Number:
PCT/IB2015/054694
Publication Date:
March 17, 2016
Filing Date:
June 23, 2015
Export Citation:
Assignee:
NOVARTIS AG (CH)
DI PADOVA FRANCO E (CH)
GHOSH JOY (US)
HUBER THOMAS (CH)
RONDEAU JEAN-MICHEL RENE (CH)
DI PADOVA FRANCO E (CH)
GHOSH JOY (US)
HUBER THOMAS (CH)
RONDEAU JEAN-MICHEL RENE (CH)
International Classes:
C07K16/24; A61K39/395; C07K14/47; A61K39/00
Domestic Patent References:
| WO2009082624A2 | 2009-07-02 | |||
| WO2014122613A1 | 2014-08-14 | |||
| WO2014099997A1 | 2014-06-26 |
Foreign References:
| US20060239965A1 | 2006-10-26 |
Other References:
DUMONT F J: "IL-17 cytokine/receptor families: Emerging targets for the modulation of inflammatory responses", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 13, no. 3, 1 March 2003 (2003-03-01), pages 287 - 303, XP002351568, ISSN: 1354-3776, DOI: 10.1517/13543776.13.3.287
Attorney, Agent or Firm:
NOVARTIS AG (Basel, CH)
Download PDF: